Liver fat content is linked to inflammatory changes in subcutaneous adipose tissue in type 2 diabetes patients

2013 ◽  
pp. n/a-n/a
Author(s):  
Henry J. Jansen ◽  
Gerald M. Vervoort ◽  
Marinette van der Graaf ◽  
Rinke Stienstra ◽  
Cees J. Tack
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Subcutaneous Adipose Tissue ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Subcutaneous Adipose ◽  
Inflammatory Changes ◽  
Diabetes Patients

Mitochondrial diabetes is associated with insulin resistance in subcutaneous adipose tissue but not with increased liver fat content

2011 ◽  
Vol 34 (6) ◽  
pp. 1205-1212 ◽  
Author(s):  
Markus M. Lindroos ◽  
Ronald Borra ◽  
Nina Mononen ◽  
Terho Lehtimäki ◽  
Kirsi A. Virtanen ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Adipose Tissue ◽  
Subcutaneous Adipose Tissue ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Mitochondrial Diabetes ◽  
Subcutaneous Adipose

Diabetes Remission Clinical Trial (DiRECT)—Plasma Liver Function Tests Reflect Change in Liver Fat Content in Early Type 2 Diabetes

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1834-P
Author(s):  
SVIATLANA V. ZHYZHNEUSKAYA ◽  
AHMAD AL-MRABEH ◽  
CARL PETERS ◽  
ALISON C. BARNES ◽  
KIEREN G. HOLLINGSWORTH ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Liver Function ◽  
Liver Function Tests ◽  
Fat Content ◽  
Diabetes Remission ◽  
Liver Fat ◽  
Early Type ◽  
Liver Fat Content

Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes

2006 ◽  
Vol 291 (2) ◽  
pp. E282-E290 ◽  
Author(s):  
Riikka Lautamäki ◽  
Ronald Borra ◽  
Patricia Iozzo ◽  
Markku Komu ◽  
Terho Lehtimäki ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Liver Steatosis ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Artery Disease ◽  
Myocardial Insulin Resistance ◽  
High Liver

Nonalcoholic fatty liver (NAFL) is a common comorbidity in patients with type 2 diabetes and links to the risk of coronary syndromes. The aim was to determine the manifestations of metabolic syndrome in different organs in patients with liver steatosis. We studied 55 type 2 diabetic patients with coronary artery disease using positron emission tomography. Myocardial perfusion was measured with [15O]H2O and myocardial and skeletal muscle glucose uptake with 2-deoxy-2-[18F]fluoro-d-glucose during hyperinsulinemic euglycemia. Liver fat content was determined by magnetic resonance proton spectroscopy. Patients were divided on the basis of their median (8%) into two groups with low (4.6 ± 2.0%) and high (17.4 ± 8.0%) liver fat content. The groups were well matched for age, BMI, and fasting plasma glucose. In addition to insulin resistance at the whole body level ( P = 0.012) and muscle ( P = 0.002), the high liver fat group had lower insulin-stimulated myocardial glucose uptake ( P = 0.040) and glucose extraction rate ( P = 0.0006) compared with the low liver fat group. In multiple regression analysis, liver fat content was the most significant explanatory variable for myocardial insulin resistance. In addition, the high liver fat group had increased concentrations of high sensitivity C-reactive protein, soluble forms of E-selectin, vascular adhesion protein-1, and intercellular adhesion molecule-1 ( P < 0.05) and lower coronary flow reserve ( P = 0.02) compared with the low liver fat group. In conclusion, in patients with type 2 diabetes and coronary artery disease, liver fat content is a novel independent indicator of myocardial insulin resistance and reduced coronary functional capacity. Further studies will reveal the effect of hepatic fat reduction on myocardial metabolism and coronary function.

scholarly journals The Mineralocorticoid Receptor Antagonist Eplerenone Suppress Interstitial Fibrosis in Subcutaneous Adipose Tissue in Type 2 Diabetes Patients

2020 ◽  
Author(s):  
Ada Admin ◽  
Marie Louise Johansen ◽  
Jaime Ibarrola ◽  
Amaya Fernández-Celis ◽  
Morten Schou ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Receptor Antagonist ◽  
Subcutaneous Adipose Tissue ◽  
Mineralocorticoid Receptor ◽  
Prostaglandin D2 ◽  
Type I ◽  
Mineralocorticoid Receptor Antagonist ◽  
Subcutaneous Adipose

Activation of the mineralocorticoid receptor (MR) may promote dysfunctional adipose tissue in patients with type 2 diabetes, where increased pericellular fibrosis has emerged as a major contributor. The knowledge of the association between the MR, fibrosis and the effects of an MR antagonist (MRA) in human adipocytes remains very limited. The present sub-study including 30 participants was prespecified as part of the Mineralocorticoid Receptor Antagonist in type 2 Diabetes (MIRAD) trial, randomizing patients to either high dose eplerenone or placebo for 26 weeks. In adipose tissue biopsies, changes in fibrosis were evaluated by immunohistological examinations and by the expression of mRNA and protein markers of fibrosis. Treatment with an MRA reduced pericellular fibrosis, synthesis of the major subunits of collagen type I and VI, and the profibrotic factor α-smooth muscle actin, as compared to placebo in subcutaneous adipose tissue. Furthermore, we found decreased expression of the MR and downstream molecules neutrophil gelatinase–associated lipocalin, galectin-3, and lipocalin-like prostaglandin D2 synthase with an MRA. In conclusions, we present original data demonstrating reduced fibrosis in adipose tissue with inhibition of the MR, which could be a potential therapeutic approach to prevent the extracellular matrix remodeling of adipose tissue in type 2 diabetes.

scholarly journals Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Diabetes Care ◽  
2019 ◽  
Vol 43 (2) ◽  
pp. 298-305 ◽  
Author(s):  
Sabine Kahl ◽  
Sofiya Gancheva ◽  
Klaus Straßburger ◽  
Christian Herder ◽  
Jürgen Machann ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Controlled Trial ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Double Blind

Lack of an association between an apolipoprotein C3 genetic variant and the liver fat content in patients with type 2 diabetes

Hepatology ◽  
2011 ◽  
Vol 54 (3) ◽  
pp. 1109-1110 ◽  
Author(s):  
Jean Michel Petit ◽  
Boris Guiu ◽  
David Masson ◽  
Jean-Pierre Cercueil ◽  
Patrick Hillon ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Genetic Variant ◽  
Fat Content ◽  
Liver Fat ◽  
Liver Fat Content ◽  
Apolipoprotein C3

Human subcutaneous adipose tissue Glut 4 mRNA expression in obesity and type 2 diabetes

2011 ◽  
Vol 50 (2) ◽  
pp. 227-232 ◽  
Author(s):  
Soumaya Kouidhi ◽  
Rym Berrhouma ◽  
Kamel Rouissi ◽  
Slim Jarboui ◽  
Marie-Stéphanie Clerget-Froidevaux ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Adipose Tissue ◽  
Mrna Expression ◽  
Subcutaneous Adipose Tissue ◽  
Glut 4 ◽  
Subcutaneous Adipose
Sign in / Sign up

Export Citation Format

Share Document